AU6291799A - Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth - Google Patents

Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth

Info

Publication number
AU6291799A
AU6291799A AU62917/99A AU6291799A AU6291799A AU 6291799 A AU6291799 A AU 6291799A AU 62917/99 A AU62917/99 A AU 62917/99A AU 6291799 A AU6291799 A AU 6291799A AU 6291799 A AU6291799 A AU 6291799A
Authority
AU
Australia
Prior art keywords
calreticulin
angiogenesis
endothelial cell
fragments
suppress tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62917/99A
Inventor
Sandra E. Pike
Giovanna Tosato
Lei Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU6291799A publication Critical patent/AU6291799A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU62917/99A 1998-10-06 1999-10-05 Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth Abandoned AU6291799A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10343898P 1998-10-06 1998-10-06
US60103438 1998-10-06
PCT/US1999/023240 WO2000020577A1 (en) 1998-10-06 1999-10-05 Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth

Publications (1)

Publication Number Publication Date
AU6291799A true AU6291799A (en) 2000-04-26

Family

ID=22295185

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62917/99A Abandoned AU6291799A (en) 1998-10-06 1999-10-05 Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth

Country Status (2)

Country Link
AU (1) AU6291799A (en)
WO (1) WO2000020577A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035986A2 (en) * 1999-11-16 2001-05-25 Hamilton Civic Hospitals Research Development Inc. Methods and compositions for modulating er-stress-induced cholesterol accumulation
JP2005512519A (en) 2001-10-01 2005-05-12 デューク・ユニバーシティ Isolated GRP94 ligand binding domain polypeptide, nucleic acid encoding the same, crystal thereof, and screening method using the same
DE60323685D1 (en) * 2002-11-01 2008-10-30 Tss Biotech Inc TUMOR MARKER FOR UROTHELIAL CANCER
EP1900375A1 (en) * 2006-09-08 2008-03-19 Institut Gustave Roussy Calreticulin for its use as a medication for the treatment of cancer in a mammal
WO2008032153A2 (en) * 2006-09-08 2008-03-20 Michel Sarkis Obeid Calreticulin for its use as a medication for the treatment of cancer in a mammal
EP1961763A1 (en) * 2007-02-21 2008-08-27 Institut Gustave Roussy Compounds regulating CRT, KDEL receptor and/or ERp-57 exposure and uses thereof to evaluate the efficiency of a cancer treatment
CA2805412C (en) 2010-06-17 2021-04-27 New York University Therapeutic and cosmetic uses and applications of calreticulin
EP3046627B1 (en) * 2013-09-18 2019-10-23 The Board of Trustees of the Leland Stanford Junior University Modulation of efferocytosis pathways for treatment of atherosclerotic disease
GB201914516D0 (en) 2019-10-08 2019-11-20 Uab Baltymas Treatment of eye disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426097A (en) * 1993-04-06 1995-06-20 The Trustees Of Columbia University In The City Of New York Calreticulin: a novel antithrombotic agent
US5591716A (en) * 1993-11-19 1997-01-07 New York University Beneficial wound healing applications of calreticulin and other hyaluronan-associated proteins
CA2140814A1 (en) * 1995-01-23 1996-07-24 Shoukat Dedhar Use of calreticulin in modulating hormone responsiveness and new pharmaceuticals for treating cancer, osteoporosis and chronic inflammatory disease
US5854202A (en) * 1995-01-24 1998-12-29 Dedhar; Shoukat Peptide fragments of calreticulin, peptide mimetics thereof, and pharmaceutical compostions comprising same
WO1996036643A1 (en) * 1995-05-17 1996-11-21 University Of Alberta Method of inhibiting restenosis using calreticulin

Also Published As

Publication number Publication date
WO2000020577A1 (en) 2000-04-13

Similar Documents

Publication Publication Date Title
WO2001023592A3 (en) Methods for making recombinant proteins using apoptosis inhibitors
HUP0103485A3 (en) Overexpression of desired proteins in eukaryotic cells mediated by cyclin di overexpression
AU5768000A (en) Personal cervical cell collector
AU3645697A (en) Amidinoindoles, amidinoazoles, and analogs thereof as inhibitors of factor xa and of thrombin
EP1097165A4 (en) Novel inhibitors of angiogenesis and tumor growth
AU6097094A (en) Antisense polynucleotide inhibition of human growth factor-sensitive cancer cells
AU4520801A (en) Novel substituted phenanthridinones and methods of use thereof
AU4992399A (en) Electrolyte gels for maintaining hydration and rehydration
AU5047600A (en) Mammalian interleukin-10 homologs: il-d110 and il-d210
AU4364897A (en) Improvements in or relating to the prophylaxis of breast cancer
AU6291799A (en) Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth
AU2001264769A1 (en) Induction of apoptosis and cell growth inhibition by protein 4.33
AU2786100A (en) Method of selecting transformed cells and tissues
AU4524899A (en) Materials and methods relating to the induction of apoptosis in target cells
AU1796501A (en) Methods of preparing electrochemical cells
AU7332800A (en) Card construction, methods of making and using
AU4187200A (en) The use of domains of type iv collagen t inhibit angiogenesis an tumour growth
AU6953100A (en) Cftr polypeptides, fragments thereof and methods of use to overcome biosyntheticmisprocessing
IL121789A0 (en) Inhibiting the growth of mammalian cells
AU1451200A (en) Dual reporter system and methods of use therefor
AU1082701A (en) Short segments of dap-kinase
AU2297201A (en) Uses of antileukoprotease in carcinoma
AU4774200A (en) Long term cell culture of human carcinoma
AU5533699A (en) Endothelial cell proliferation inhibitors derived from human prothrombin
AU2881999A (en) Detection of metastatic cancer cells using pcta-1

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase